HEMARINA Announces a Major Publication in The American Journal of Transplantation

HEMARINA has announced the publication of a study demonstrating the major benefits of HEMO2life® in comparison to the organ preservation solutions currently used in private hospitals (Thuillier et al. Supplementation With a New Therapeutic Oxygen Carrier Reduces Chronic Fibrosis and Organ Dysfunction in Kidney Static Preservation, American Journal of Transplantation. 2011; 11(9):1845-1860).

This study confirms the efficiency of the innovative technology developed by HEMARINA. The in vivo trials show that the addition of HEMO2life® to the most frequently used preservation solutions on the market leads to better preservation and faster recovery of kidney function after transplantation.

Therefore, on the short term, the use of HEMO2life® promotes immediate organ function and, on the long term, it reduces inflammation and thus leads to better preservation of organ integrity.

These results demonstrate that the transplant performed with a kidney preserved in a HEMO2life®-supplemented solution has better prognosis for transplant success and for organ recovery post-transplantation.

HEMO2life® maintains the transplant organ in better conditions by providing continuous oxygenation, according to the organ’s needs and without causing oxidative stress.

“HEMARINA is delighted to have finalized HEMO2life® so quickly. HEMO2life® is an innovative solution that protects grafts and grafts are a second chance for patients to live normally. Because transplant organs are becoming rarer, it is essential to preserve them in the best possible conditions and avoid the problem of delayed graft function, which can damage the organ,” declared Franck Zal, Ph.D., co-founder and General and Scientific Director of HEMARINA.

Zal continued, "Since Hemo2life is a secondary therapeutic product, the marketing authorization process is shorter than for drugs and we predict that this solution will be available for graft preservation in France as of 2012."

Given the current shortage of transplant organs, these positive results mark an important step in the field of transplantation. Not only should HEMO2life® improve the transplant success rate, but it also should enhance “borderline” organs and thus increase the number of grafts available for transplant.

Finally, by improving post-transplant kidney function, HEMO2life® should decrease the need for dialysis in transplant patients. Dialysis is an expensive medical routine and very costly for the health-care system.

This study was conducted in conjunction the CNRS UMR 7144 research unit directed by Professor François Lallier (CNRS and UPMC University Paris 6), the INSERM U927 research unit led by Professor Thierry Hauet in Poitiers, and the IBiSA “Surgery, Experimentation, Transplantation” facility at INRA (Domaine Expérimental du Magneraud).